Nothing Special   »   [go: up one dir, main page]

ATE478602T1 - Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen - Google Patents

Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen

Info

Publication number
ATE478602T1
ATE478602T1 AT05858653T AT05858653T ATE478602T1 AT E478602 T1 ATE478602 T1 AT E478602T1 AT 05858653 T AT05858653 T AT 05858653T AT 05858653 T AT05858653 T AT 05858653T AT E478602 T1 ATE478602 T1 AT E478602T1
Authority
AT
Austria
Prior art keywords
protein
receptor
precursor
polypeptide
alpha
Prior art date
Application number
AT05858653T
Other languages
English (en)
Inventor
S Karumanchi
Vikas Sukhatme
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE478602T1 publication Critical patent/ATE478602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05858653T 2004-12-15 2005-12-15 Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen ATE478602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63627504P 2004-12-15 2004-12-15
PCT/US2005/045805 WO2007053161A2 (en) 2004-12-15 2005-12-15 Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy

Publications (1)

Publication Number Publication Date
ATE478602T1 true ATE478602T1 (de) 2010-09-15

Family

ID=38006337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05858653T ATE478602T1 (de) 2004-12-15 2005-12-15 Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen

Country Status (12)

Country Link
US (1) US7955805B2 (de)
EP (1) EP1839057B1 (de)
JP (1) JP2008523816A (de)
KR (1) KR20070092737A (de)
CN (1) CN101299962A (de)
AT (1) ATE478602T1 (de)
AU (1) AU2005337873A1 (de)
BR (1) BRPI0519096A2 (de)
CA (1) CA2591142A1 (de)
DE (1) DE602005023216D1 (de)
HK (1) HK1115286A1 (de)
WO (1) WO2007053161A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1804836B1 (de) 2004-09-24 2010-11-17 Beth Israel Deaconess Medical Center Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
JP5009811B2 (ja) 2004-12-21 2012-08-22 イェール ユニバーシティ 子癇前症の検出
US7230561B2 (en) * 2005-01-27 2007-06-12 Micron Technology, Inc. Programmable integrating ramp generator and method of operating the same
WO2006102498A2 (en) * 2005-03-24 2006-09-28 Beth Israel Deaconess Medical Center Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy
WO2007030889A1 (en) * 2005-09-15 2007-03-22 Victor Voroteliak Method of diagnosing pre-eclampsia
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
AU2008209319A1 (en) * 2007-01-25 2008-07-31 Crc For Asthma And Airways Ltd Method of diagnosis
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
EP2037278A1 (de) * 2007-09-11 2009-03-18 F.Hoffmann-La Roche Ag Gefäßmarker bei der Neumodellierung von Herzkrankheiten
WO2010033553A2 (en) * 2008-09-16 2010-03-25 University Of Florida Research Foundation Inc. Gene expression related to preeclampsia
US9229009B2 (en) 2008-10-31 2016-01-05 Yale University Methods and kits for detecting misfolded proteins
ES2530574T3 (es) * 2009-01-28 2015-03-03 Ind Tech Res Inst Biomarcadores asociados a la nefropatía
EP2625524A4 (de) * 2010-10-07 2014-05-07 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
ES2667013T3 (es) * 2010-11-29 2018-05-09 Mote Marine Laboratory, Inc. Determinación de las características sexuales de peces usando hormonas peptídicas
KR101114446B1 (ko) * 2011-02-25 2012-02-24 건국대학교 산학협력단 프로테오믹스기법을 이용한 임신중독 특이 표지 단백질 및 진단방법
CN102192987B (zh) * 2011-02-25 2014-04-02 复旦大学附属上海市第五人民医院 一种用于妊娠高血压疾病诊断的试剂盒
ES2614059T3 (es) 2011-03-17 2017-05-29 Cedars-Sinai Medical Center Biomarcador de diagnóstico para predecir las mujeres en riesgo de parto prematuro
AU2012346594B2 (en) * 2011-11-30 2017-12-21 Agency For Science, Technology And Research GM1 ganglioside to Annexin V microparticle polypeptide ratio for biological monitoring
AU2013207264A1 (en) * 2012-01-06 2014-07-17 Bg Medicine, Inc. Use of galectin-3 for risk assessment and detection of preeclampsia and related conditions
CN104634982B (zh) * 2013-11-06 2016-08-17 中国科学院上海生命科学研究院 Vegf-c在制备败血症及重症细菌感染诊断试剂中的用途
CN103760340B (zh) * 2014-01-28 2016-11-23 成都创宜生物科技有限公司 以flrg作为标志物制备检测工具的应用及检测工具
US10324094B2 (en) 2014-04-10 2019-06-18 Yale University Methods and compositions for detecting misfolded proteins
RU2724013C2 (ru) 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
CN106771266A (zh) * 2017-01-12 2017-05-31 广州市丰华生物工程有限公司 抑制素a定量检测试剂盒及其制备方法
JP6895165B2 (ja) * 2017-06-06 2021-06-30 知和 松浦 α１−アンチキモトリプシンを含むバイオマーカー
US20210325400A1 (en) * 2020-04-16 2021-10-21 Denali K. Dahl Preeclampsia diagnostic devices, systems and methods
CN111951969A (zh) * 2020-08-05 2020-11-17 中翰盛泰生物技术股份有限公司 Hbp在高危妊娠预测中的应用
CN114075281B (zh) * 2021-11-16 2023-04-18 福州迈新生物技术开发有限公司 抗Inhibin-α蛋白单克隆抗体、细胞系及其制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079171A (en) * 1988-09-15 1992-01-07 Adeza Biomedical Corporation Determining pregnancy induced hypertension and eclampsia by immunoassay of cellular fibronectin
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5238819A (en) * 1988-12-14 1993-08-24 The Regents Of The University Of California Diagnostic assay for the detection of preeclampsia
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5543138A (en) * 1994-03-10 1996-08-06 Genetics Institute, Inc. Methods of diagnosing and treating preeclampsia
GB9512994D0 (en) * 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
US6361946B1 (en) * 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6399585B1 (en) * 1996-05-15 2002-06-04 Janet E. Larson In Utero treatment of CFTR-related deficiencies
JP4318752B2 (ja) * 1996-05-31 2009-08-26 ヘルス・リサーチ・インコーポレーテッド 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用
US6620590B2 (en) * 1996-07-11 2003-09-16 Isis Innovation Limited Diagnosis of pre-eclampsia
EP0951298A1 (de) 1996-12-23 1999-10-27 Cambridge University Technical Services Limited Diagnose und behandlung von pathologischen schwangerschaften
EP0968430A1 (de) * 1997-03-07 2000-01-05 Mount Sinai Hospital Corporation Verfahrens zur diagnose einer benötigten regulierung der trophoblastinvasion
EP1417971A3 (de) 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US6245577B1 (en) * 1998-09-11 2001-06-12 Midland Bioproducts Corporation IgG antibody testing method
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0026823D0 (en) * 2000-11-02 2000-12-20 King S College London Diagnosis of pre-eclampsia
WO2002070535A1 (en) * 2001-03-01 2002-09-12 Isis Pharmaceuticals, Inc. Antisense modulation of recql5 expression
EP1466016A2 (de) * 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Krebsprofile
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
OA12890A (en) * 2002-07-19 2006-10-13 Beth Israel Hospital Methods of diagnosing and treating pre-eclampsia or eclampsia.
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN101245376A (zh) * 2003-01-17 2008-08-20 香港中文大学 作为妊娠相关病症的诊断标志物的循环mRNA
US20050266409A1 (en) 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
DE10333105B3 (de) * 2003-07-21 2005-05-25 OCé PRINTING SYSTEMS GMBH Einrichtung zur Einstellung der Spannung einer Materialbahn, die durch eine die Materialbahn bearbeitende Prozessstation bewegt wird
WO2005017192A2 (en) * 2003-08-14 2005-02-24 The General Hospital Corporation Screening for gestational disorders
US7344892B2 (en) * 2003-09-23 2008-03-18 Beth Israel Deaconess Medical Center, Inc. Screening for gestational disorders
EP1804836B1 (de) 2004-09-24 2010-11-17 Beth Israel Deaconess Medical Center Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
JP5009811B2 (ja) * 2004-12-21 2012-08-22 イェール ユニバーシティ 子癇前症の検出
WO2008030283A1 (en) 2006-05-31 2008-03-13 Beth Israel Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy

Also Published As

Publication number Publication date
US20060166277A1 (en) 2006-07-27
EP1839057B1 (de) 2010-08-25
BRPI0519096A2 (pt) 2008-12-23
WO2007053161A3 (en) 2007-11-29
US7955805B2 (en) 2011-06-07
EP1839057A2 (de) 2007-10-03
JP2008523816A (ja) 2008-07-10
CN101299962A (zh) 2008-11-05
AU2005337873A1 (en) 2007-05-10
WO2007053161A2 (en) 2007-05-10
DE602005023216D1 (de) 2010-10-07
HK1115286A1 (en) 2008-11-28
EP1839057A4 (de) 2008-12-31
KR20070092737A (ko) 2007-09-13
CA2591142A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE478602T1 (de) Nukleinsäuren und polypeptide zur diagnose und behandlung von schwangerschaftskomplikationen
Pollheimer et al. Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast
Furukawa et al. p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts
Halasz et al. The role of progesterone in implantation and trophoblast invasion
Klein et al. Wnt2 acts as a cell type–specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross‐stimulating the VEGF pathway
Malaterre et al. c-Myb is required for neural progenitor cell proliferation and maintenance of the neural stem cell niche in adult brain
Xu et al. Expression of TGF-β signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells
JP2008523816A5 (de)
Chen et al. N-Terminomics identifies HtrA1 cleavage of thrombospondin-1 with generation of a proangiogenic fragment in the polarized retinal pigment epithelial cell model of age-related macular degeneration
Winiarski et al. Epithelial ovarian cancer-induced angiogenic phenotype of human omental microvascular endothelial cells may occur independently of VEGF signaling
Bumke et al. Modulation of gene expression by extracellular pH variations in human fibroblasts: a transcriptomic and proteomic study
Kobayashi et al. The ferroimmunomodulatory role of ectopic endometriotic stromal cells in ovarian endometriosis
Mentlein et al. Functional significance of vascular endothelial growth factor receptor expression on human glioma cells
Moin et al. Tumor cell membrane cathepsin B
KR20100044793A (ko) 신경퇴행성 질환에서 ｃｄ44 접목 변이체들
Meng et al. Expression of platelet-derived growth factor B is upregulated in patients with thoracic aortic dissection
Zhang et al. Adrenomedullin enhances invasion by trophoblast cell lines
Brkić et al. Differential role of Smad2 and Smad3 in the acquisition of an endovascular trophoblast-like phenotype and preeclampsia
Xu et al. Reconstitution of Smad3 restores TGF-β response of tissue inhibitor of metalloprotease-1 upregulation in human choriocarcinoma cells
Eckharter et al. Schwann cell expressed Nogo-B modulates axonal branching of adult sensory neurons through the Nogo-B receptor NgBR
Lecca et al. Fibrotic response in fibroblasts from congenital disorders of glycosylation
US10415093B2 (en) Method for diagnosing and monitoring inflammatory disease progression
Luchetti et al. Scleroderma fibroblasts constitutively express the long pentraxin PTX3
Cho et al. Bone-related gene profiles in developing calvaria
Seidel et al. The promyelocytic leukemia zinc finger (PLZF) protein exerts neuroprotective effects in neuronal cells and is dysregulated in experimental stroke

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties